New Blood Test Detects Cancer Treatment Success in Real Time

Cancer patients may soon know within weeks whether their treatment is working, thanks to a blood test that detects tumor DNA circulating in the bloodstream.

Researchers presented data at the American Association for Cancer Research meeting showing how the test tracks treatment response in colorectal and lung cancer patients. The technology monitors tiny fragments of tumor DNA that cancer cells shed into the blood, offering a real-time window into how tumors respond to therapy.

The results from colorectal cancer patients were striking. Patients whose blood tests showed tumor DNA disappearing by the second treatment cycle had a 100% chance of their tumors shrinking completely. Meanwhile, those whose tumor DNA levels stayed steady didn't respond to treatment at all.

Dr. Jiang from University College London presented findings from 10,000 patients tracked through 25,000 blood samples. The test caught cancer recurrence with perfect accuracy after surgery, identifying patients who needed additional treatment before tumors became visible on scans.

The technology goes beyond simple detection. A new feature tracks specific mutations that signal drug resistance as they develop, catching problems like ESR1 mutations in breast cancer before treatments stop working. Among patients with detectable tumor DNA, 38% showed resistance mutations that doctors could act on immediately.

Lung cancer patients receiving immunotherapy saw equally promising results. Those whose blood tests showed complete tumor DNA clearance remained cancer-free three years later. Patients without that clearance faced five times higher odds of their cancer returning.

The test works at extraordinary sensitivity levels, detecting tumor DNA at concentrations as low as two parts per million. That ultrasensitive detection caught 14.6% of positive results that less sensitive tests would have missed entirely.

Why This Inspires

This breakthrough transforms cancer monitoring from an anxious waiting game into an active partnership between patients and doctors. Instead of enduring months of ineffective treatment while waiting for the next scan, patients could switch to better options within weeks based on their blood test results.

The technology works across 14 different cancer types and various disease stages, meaning its benefits could extend far beyond colorectal and lung cancers. For patients facing the uncertainty of cancer treatment, having clear molecular evidence of progress offers both peace of mind and better outcomes.

The shift from reactive to proactive cancer care represents exactly the kind of precision medicine researchers have promised for years, now finally delivering real-world results that save lives and spare suffering.

Thousands of patients are already benefiting from this technology, and its expanding use promises to make cancer treatment more effective and less burdensome for countless more.